Acrivon Therapeutics, Inc. (ACRV)
| Market Cap | 62.48M |
| Revenue (ttm) | n/a |
| Net Income | -81.75M |
| EPS | -2.13 |
| Shares Out | 31.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 572,110 |
| Open | 1.910 |
| Previous Close | 1.940 |
| Day's Range | 1.910 - 2.009 |
| 52-Week Range | 1.050 - 8.000 |
| Beta | 1.75 |
| Analysts | Buy |
| Price Target | 13.00 (+556.57%) |
| Earnings Date | Nov 13, 2025 |
About ACRV
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is AC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ACRV stock is "Buy." The 12-month stock price target is $13.0, which is an increase of 556.57% from the latest price.
News
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company's recent interim clinical data from the ongoing, registra...
Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls
Acrivon Therapeutics Inc. (NASDAQ: ACRV) on Thursday shared updates regarding the Phase 2 ACR-368 program and initial clinical data from the ACR-2316 Phase 1 study.
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall...
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p...
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial ...
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing p...
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR...
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% ...
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observe...
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of car...
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the P...
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Acrivon Therapeutics is developing a targeted oncology therapy with a companion proteomics-based signature, showing promising activity in their lead compound for certain patients with gynecologic canc...
Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity
- First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon's robust pipeline, incl...
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis
WATERTOWN, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon ...
Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?
Acrivon Therapeutics, Inc. is an oncology-focused biotech using a multi-targeted panel to identify patients for clinical trials. Acrivon Therapeutics is focused on ACR-368, a CHK1/2 inhibitor, with pr...
Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onc...
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision onco...
Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data
Shares of Acrivon Therapeutics ACRV, -3.26% advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovaria...
Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall ...
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision on...
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan
ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in precl...